Global Erectile Dysfunction Drugs Market 2014-2018

About Erectile Dysfunction Drugs
A man's failure to sustain an erection that is adequate enough for sexual activity is known as erectile dysfunction. It also refers to the inconsistency to do so, or the inability to endure it for an extended period. Erectile dysfunction can be due to a number of reasons including aging, high blood pressure, diabetes mellitus, depression, smoking, nerve or spinal cord damage, alcoholism, and low testosterone levels. Treatments for erectile dysfunction include adopting a healthy lifestyle, oral phosphodiesterase type 5 (PDE5) inhibitors, vacuum devices, and surgery. Erectile dysfunction affects the quality of life and leads to stress, anxiety, and self-confidence problems. New research is undergoing in the field of erectile dysfunction to find more enhanced and effective therapies.
TechNavio's analysts forecast the Global Erectile Dysfunction Drugs market to decline at a CAGR of 4.47 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Erectile Dysfunction Drugs market for the period 2014-2018. The Global Erectile Dysfunction Drugs market can be divided into six segments: PDE 5 Inhibitors, Vacuum Constriction Device, Penile Prosthesis, Vascular Reconstructive Surgery, Injection Therapies, and Testosterone Replacement Therapy. To calculate the market size, the report considers the revenue generated from the sales of various drugs and topical creams used for the treatment of erectile dysfunction.
TechNavio's report, the Global Erectile Dysfunction Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Erectile Dysfunction Drugs market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key Regions
‧ Americas
‧ APAC
‧ EMEA
Key Vendors
‧ Apricus Biosciences
‧ Bayer
‧ Dong-A Socio Holdings
‧ Eli Lily
‧ Pfizer
‧ Vivus
Other Prominent Vendors
‧ Auxillium Pharmaceuticals
‧ Cristalia Produtos Quimicos Farmaceuticos
‧ Futura Medical
‧ Johnson & Johnson
‧ Meda Pharmaceuticals
‧ Pacific Therapeutics
‧ Seattle Genetics
Market Driver
‧ Increase in Aging Population
‧ For a full, detailed list, view our report
Market Challenge
‧ High Cost
‧ For a full, detailed list, view our report
Market Trend
‧ Increased Awareness of Erectile Dysfunction
‧ For a full, detailed list, view our report
Key Questions Answered in this Report
‧ What will the market size be in 2018 and what will the growth rate be?
‧ What are the key market trends?
‧ What is driving this market?
‧ What are the challenges to market growth?
‧ Who are the key vendors in this market space?
‧ What are the market opportunities and threats faced by the key vendors?
‧ What are the strengths and weaknesses of the key vendors?

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Market Segmentation by Treatment
08. Market Assessment of Top Drugs
08.1 Viagra
08.1.1 Historic Sales
08.2 Cialis
08.2.1 Historic Sales
08.3 Levitra
08.3.1 Historic Sales
09. Competitive Assessment of Top Drugs
10. Geographical Segmentation
11. Buying Criteria
12. Rate of Incidence and Prevalence
13. Market Growth Drivers
14. Drivers and their Impact
15. Market Challenges
16. Impact of Drivers and Challenges
17. Market Trends
18. Trends and their Impact
19. Vendor Landscape
19.1 Competitive Scenario
19.1.1 Key News
19.1.2 Mergers and Acquisitions
19.2 Market Share Analysis 2013
19.3 Other Prominent Vendors
20. Key Vendor Analysis
20.1 Apricus Biosciences
20.1.1 Key Facts
20.1.2 Business Overview
20.1.3 Geographical Segmentation by Revenue 2013
20.1.4 Business Strategy
20.1.5 Recent Developments
20.1.6 SWOT Analysis
20.2 Bayer AG
20.2.1 Key Facts
20.2.2 Business Overview
20.2.3 Business Segmentation
20.2.4 Business Strategy
20.2.5 Sales Segmentation by Business
20.2.6 Sales by Geographical Segmentation
20.2.7 Key Information
20.2.8 SWOT Analysis
20.3 Dong-A Socio
20.3.1 Key Facts
20.3.2 Business Overview
20.3.3 Business Segmentation
20.3.4 Geographical Segmentation by Revenue 2013
20.3.5 Business Strategy
20.3.6 Recent Developments
20.3.7 SWOT Analysis
20.4 Eli Lilly and Co.
20.4.1 Key Facts
20.4.2 Business Overview
20.4.3 Business Segmentation by Revenue 2013
20.4.4 Business Segmentation by Revenue 2012 and 2013
20.4.5 Sales by Geography
20.4.6 Business Strategy
20.4.7 Key Developments
20.4.8 SWOT Analysis
20.5 Pfizer Inc.
20.5.1 Key Facts
20.5.2 Business Description
20.5.3 Business Segmentation
20.5.4 Revenue by Business Segmentation
20.5.5 Revenue Comparison 2012 and 2013
20.5.6 Sales by Geography
20.5.7 Business Strategy
20.5.8 Key Developments
20.5.9 SWOT Analysis
20.6 Vivus
20.6.1 Key Facts
20.6.2 Business Overview
20.6.3 Business Segmentation by Revenue 2013
20.6.4 Business Segmentation by Revenue 2012 and 2013
20.6.5 Geographical Segmentation by Revenue 2013
20.6.6 Business Strategy
20.6.7 Recent Developments
20.6.8 SWOT Analysis
21. Other Reports in this Series

List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Erectile Dysfunction Drugs Market 2013-2018 (US$ billion)
Exhibit 3: Global Erectile Dysfunction Drugs Market Segmentation by Treatment
Exhibit 4: Pfizer's Viagra Revenue 2010-2013 (US$ million)
Exhibit 5: Eli Lily's Cialis Revenue 2010-2013 (US$ million)
Exhibit 6: Bayer's Levitra Revenue 2010-2013 (US$ million)
Exhibit 7: Sales of Top 3 Erectile Dysfunction Drugs FY 2010-2013 (US$ million)
Exhibit 8: Sales of Top 3 Erectile Dysfunction Drugs FY 20010-2013 (US$ million)
Exhibit 9: Global Erectile Dysfunction Drugs Market by Geographical Segmentation 2013
Exhibit 11: Apricus Biosciences: Geographical Segmentation by Revenue 2013
Exhibit 12: Business Segmentation of Bayer AG 2013
Exhibit 13: Sales Comparison of Bayer AG by Business Segment 2012 and 2013 (US$ million)
Exhibit 14: Sales Segmentation of Bayer AG by Geography 2013
Exhibit 15: Dong-A Socio: Business Segmentation 2013
Exhibit 16: Dong-A Socio: Geographical Segmentation by Revenue 2013
Exhibit 17: Eli Lilly and Co.: Business Segmentation by Revenue 2013
Exhibit 18: Eli Lilly and Co.: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 19: Eli Lilly and Co.: Sales by Geography 2013
Exhibit 20: Pfizer Inc.: Business Segmentation
Exhibit 21: Pfizer Inc.: Revenue by Business Segmentation 2013
Exhibit 22: Pfizer Inc.: Revenue by Business Segmentation 2012 and 2013
Exhibit 23: Pfizer Inc.: Revenue by Geography 2013
Exhibit 24: Global Erectile Dysfunction Drugs Market: Business Segmentation by Revenue 2013
Exhibit 25: Global Erectile Dysfunction Drugs Market: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 26: Global Erectile Dysfunction Drugs Market: Geographical Segmentation by Revenue 2013